Environmental toxicants and Parkinson's disease: recent evidence, risks, and prevention opportunities
- PMID: 41109237
- DOI: 10.1016/S1474-4422(25)00287-X
Environmental toxicants and Parkinson's disease: recent evidence, risks, and prevention opportunities
Abstract
The global burden of Parkinson's disease is rising. Large-scale genetic studies have confirmed that extrinsic or environmental factors, rather than genetic predisposition, play a dominant role in its cause. Increasing evidence implicates three classes of toxicants-certain pesticides, the dry-cleaning chemicals trichloroethylene and perchloroethylene, and air pollution-in the development of Parkinson's disease. These toxicants are widely prevalent, impair mitochondrial or lysosomal function, or both, and contribute to, if not cause, the disease. Parkinson's disease could be thus largely preventable. Uncertainties remain regarding the relevant doses, timing, and routes of exposure, the nature of genetic and environmental interactions, the effects of combined exposures, the role of the microbiome, and the identity of other environmental risks. Methodological limitations and structural challenges hinder our understanding. However, improved measurement of toxicant exposure in individuals and the environment, long-term prospective studies, increased funding for prevention, and policy changes can precipitate the fall of the burden of Parkinson's disease.
Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests ERD has received grants from Averitas Pharma, Biogen, Burroughs Wellcome Fund, Michael J Fox Foundation, US National Institutes of Health (NIH), Pfizer, PhotoPharmics, Roche, Edmond J Safra Foundation, Golisano Foundations; royalties from Public Affairs; consulting fees from Mediflix, Karger, Genentech/Roche, BioSensics, Cerevance, Biohaven Pharmaceuticals, VivoSense, HanAll, NACCME, NIH, Sutter Home, Deallus, Medscame, Seelos Therapeutics, and Eden McCallum; honoraria from WebMD, American Neurological Association, HMP Education, ADIVO Associates France, University of Toronto, Novartis, Philadelphia Neurological Society, Stony Brook, and Dartmouth; and has ownership interests in Included Health, Mediflix, SemCap, and Synapticure. BRDM has received grants from NIH, US Department of Defense, the Parkinson's Foundation, and the American Parkinson's Disease Association; consulting fees from The Miller Firm, Bell Legal Group; honoraria from the Parkinson's Foundation, American Parkinson's Disease Association, and Michael J Fox Foundation. BRB has received grants from Biogen, Cure Parkinson's, Davis Phinney Foundation, Edmond J Safra Foundation, Fred Foundation, Gatsby Foundation, Hersenstichting Nederland, Horizon 2020, IRLAB Therapeutics, Maag Lever Darm Stichting, Michael J Fox Foundation, the Netherlands Ministry of Agriculture, Ministry of Economic Affairs & Climate Policy, and Ministry of Health, Welfare and Sport, Netherlands Organization for Scientific Research, Not Impossible, Parkinson Vereniging, Parkinson's Foundation, Parkinson's UK, Stichting Alkemade-Keuls, Stichting Parkinson NL, Stichting Woelse Waard, Topsector Life Sciences and Health, UCB, Verily Life Sciences, Roche, and Zambon; consulting fees from Critical Path Institute, Gyenno Science, UCB, and Zambon; and honoraria from AbbVie, Bial, Biogen, GE Healthcare, Oruen, Roche, UCB, and Zambon. AE has received grants from the Michael J Fox Foundation, the French Ministry of Agriculture, ANR, and France Parkinson; and honoraria from the Prada Foundation. JL-G has received grants from the Michael J Fox Foundation and the Alzheimer's Association; and consulting fees from the Davos Alzheimer's Collaborative. SMG has received grants from the Michael J Fox Foundation, NIH, the US Health Resources and Services Administration, the US Veterans Administration, US National Institute for Occupational Safety and Health, US Department of Defense, and the US Agency for Toxic Substances and Diseases Registry; and consulting fees from Michael J Fox Foundation, Alkahest, and Littlepage Booth. CMT has received grants from the Parkinson's Foundation, the Michael J Fox Foundation, Gateway, Roche Genentech, Biogen, NIH, US Department of Defense, Parkinson's Foundation, Parkinson Study Group, US Veterans Administration, and Marcus Program in Precision Medicine; consulting fees from Bial, CNS Ratings, Grey Matter, Jazz/Cavion, and Praxis; honoraria or payment from Guidemark Health, American Academy of Neurology, Beth Israel Deaconess, Rush University Medical Center, Mt Sinai, University of Luxembourg, International Association of Parkinsonism and Related Disorders, International Parkinson's Disease & Movement Disorders Society, Medical University of South Carolina, Fondazione Prada, Acadia, Northwestern University, Partners Health, Neurocrine, Lundbeck, Cadent, Acorda, Supernus, Amneal, Kyowa Kirin, Jazz/Cavion, Australia Parkinson's Mission, Evidera, Biogen, Praxis, Roche-Genentech, and Bial. All other authors declare no competing interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
